Want to see TSE:AIML full AI Analyst Report?
Aiml Resources (AIML) AI Stock Analysis
Aiml Resources
(CNQX:AIML)
The score is driven primarily by very weak financial performance—shrinking tiny revenue, negative gross profit, large ongoing losses, accelerating cash burn, and negative equity. Technical indicators provide only limited support with mixed momentum signals, and valuation remains unattractive due to losses (negative P/E) and no dividend yield.
Aiml Resources (AIML) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 13.43M
- Dividend Yield
- ―
- Average Volume (3M)
- 248.28K
- Price to Earnings (P/E)
- -1.7
- Beta (1Y)
- 1.36
- Revenue Growth
- -73.93%
- EPS Growth
- 23.46%
- Country
- Canada
- Employees
- 3
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Aiml Resources Business Overview & Revenue Model
Company Description
Operating within the digital healthcare sector, AI/ML Innovations Inc. harnesses the power of artificial intelligence (AI) and machine learning (ML). The company's central offering is a patent-pending system for personal health monitoring and managem...
How the Company Makes Money
Reliable, source-verifiable details on Aiml Resources (AIML)'s revenue model, key revenue streams, and material partnerships or drivers of earnings are not available from the context provided. null
Aiml Resources Financial Statement Overview
Summary
Financial performance is very weak: TTM revenue is extremely small and down sharply (~-47%), gross profit is negative, and net losses remain around -6.6M. Cash burn is accelerating (TTM operating cash flow and free cash flow both about -5.7M). The balance sheet adds risk with negative stockholders’ equity and rising debt relative to a modest asset base, implying continued reliance on external capital.
Income Statement
9Very NegativeBalance Sheet
18Very NegativeCash Flow
11Very Negative| Breakdown | TTM | Jul 2026 | Jul 2025 | Jul 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 83.06K | 83.06K | 167.31K | 600.14K | 487.50K | 65.41K |
| Gross Profit | -554.88K | -2.75M | 162.81K | 294.86K | 466.01K | 65.41K |
| EBITDA | -6.40M | -6.39M | -4.83M | -1.67M | -1.36M | -3.42M |
| Net Income | -6.36M | -6.36M | -4.59M | -3.29M | -1.42M | -3.17M |
Balance Sheet | ||||||
| Total Assets | 2.07M | 2.07M | 3.41M | 329.69K | 1.51M | 2.04M |
| Cash, Cash Equivalents and Short-Term Investments | 257.77K | 257.77K | 2.00M | 216.86K | 14.56K | 525.24K |
| Total Debt | 962.20K | 962.20K | 198.19K | 197.72K | 859.98K | 261.34K |
| Total Liabilities | 2.89M | 2.89M | 855.77K | 1.54M | 1.79M | 1.55M |
| Stockholders Equity | -785.25K | -785.25K | 2.60M | -1.17M | -247.46K | 1.08M |
Cash Flow | ||||||
| Free Cash Flow | -5.41M | -5.41M | -3.99M | -1.64M | -634.28K | -3.02M |
| Operating Cash Flow | -5.41M | -5.41M | -3.99M | -1.64M | -634.28K | -3.02M |
| Investing Cash Flow | -4,669 | -4,669 | -1,151 | -325.98K | -210.64K | -1.14M |
| Financing Cash Flow | 3.67M | 3.67M | 5.78M | 2.16M | 374.37K | 1.27M |
Aiml Resources Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AIML, the sentiment is Negative. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.04, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 43.46 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AIML.
Aiml Resources Peers Comparison
Overall Rating
- TSE:AIML42Neutral
TSE:CHS41Neutral
TSE:UDOC41Neutral
TSE:ADK40Underperform
TSE:DMED39Underperform
TSE:NARA38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:AIML | 42Neutral | CAD 13.43M | -1.72 | 2759.13% | ― | -73.93% | 23.46% |
| TSE:CHS | 41Neutral | CAD 10.29M | -1.76 | 64.52% | ― | 7.63% | -106.03% |
| TSE:UDOC | 41Neutral | CAD 5.18M | -1.59 | 355.56% | ― | 614.03% | 51.97% |
| TSE:ADK | 40Underperform | CAD 40.34M | -8.11 | 9999.00% | ― | -36.92% | 13.03% |
| TSE:DMED | 39Underperform | CAD 3.95M | -1.94 | 739.84% | ― | ― | -28.35% |
| TSE:NARA | 38Underperform | CAD 2.39M | -0.82 | 184.91% | ― | ― | 43.30% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:AIML | Aiml Resources Inc. | 0.04 | -0.01 | -25.00% | |
| TSE:ADK | Diagnos Inc | 0.34 | -0.01 | -1.47% | |
| TSE:CHS | Comprehensive Healthcare Systems Inc | 0.35 | -0.27 | -42.74% | |
| TSE:UDOC | Unidoc Health Corp. | 0.06 | -0.13 | -68.42% | |
| TSE:NARA | PanGenomic Health, Inc. Class A | 0.17 | -1.03 | -85.83% | |
| TSE:DMED | DiagnaMed Holdings Corp. | 0.03 | -0.06 | -66.67% |
Aiml Resources Corporate Events
AIML’s NeuralCloud Partners with Etisense to Embed AI ECG Engine in Preclinical Animal Research
PositiveNeuralCloud Solutions, the wholly owned subsidiary of AI/ML Innovations Inc., has entered into a non-exclusive agreement with Lyon-based Etisense SAS to integrate its MaxYield ECG signal-processing engine into Etisense’s LASA telemetry software...
AI/ML Innovations Tightens Governance With New Advance Notice Rules for Director Nominations
PositiveAI/ML Innovations Inc., a global digital health technology firm, specializes in applying artificial intelligence and neural networks to biometric data to generate actionable clinical insights. Through advanced signal processing and deep learning, the...
AI/ML Innovations Converts Service Debt to Equity in Share Issuance
PositiveAI/ML Innovations Inc., a global provider of AI-driven digital health technologies, develops neural-network-based platforms that convert biometric data into clinical insights to support early diagnosis and personalized care. The company is listed on...
AI/ML Innovations Names New CFO and Issues Shares to Settle Debt
PositiveAI/ML Innovations Inc., a global technology firm specializing in artificial intelligence and neural-network solutions for digital health, develops platforms that transform biometric data into clinical insights to improve diagnosis, treatment personal...
AIML’s NeuralCloud Strikes VetMed Deal to Validate MaxYield ECG Tech in Preclinical Cardiac Safety
PositiveAI/ML Innovations’ subsidiary NeuralCloud Solutions has signed a binding commercial term sheet and service level agreement with VetMed Consultants to evaluate the use of its MaxYield ECG signal-processing technology in preclinical cardiac safet...
NeuralCloud and RKS Medical Partner to Pilot Integrated CardioYield Cardiac Monitoring Platform
PositiveNeuralCloud Solutions, a subsidiary of AI/ML Innovations Inc., has entered a strategic partnership with Toronto-based RKS Medical Technologies to pair NeuralCloud’s CardioYield software with RKS’s myPatch wireless Holter monitoring device...
AI/ML Innovations Launches Quantum Soma Contactless Quantum Biosensing Initiative
PositiveAI/ML Innovations has launched Quantum Soma, a new project to develop a contactless quantum biosensing platform that marries Dynex Quantum Technologies’ NV-diamond quantum sensors with AIML’s MaxYield signal-intelligence engine. The initi...
AI/ML’s NeuralCloud Taps Former FDA Lead Reviewer to Head Regulatory Strategy
PositiveAI/ML Innovations’ subsidiary NeuralCloud has appointed former U.S. FDA lead reviewer and scientist Dr. Mehmet A. Kosoglu as Head of Regulatory, adding more than 15 years of experience in medical devices, SaMD, digital health and FDA policy to...
NeuralCloud to Pilot AI ECG Platforms with Island Mobile Cardiology Testing
PositiveNeuralCloud Solutions Inc., a subsidiary of AI/ML Innovations Inc., has signed a non-binding commercial term sheet with Island Mobile Cardiology Testing to run a pilot of its MaxYield and CardioYield platforms in a mobile Holter monitoring workflow o...
AI/ML Innovations Plans $2 Million Private Placement to Fund Digital Health Expansion
PositiveAI/ML Innovations Inc., a global AI-driven digital health company, develops proprietary platforms that apply neural networks and deep learning to complex biometric data. Its technology is designed to generate actionable clinical insights that support...
NeuralCloud Gains ISO 13485 MDSAP Certification for ECG AI Medical Software
PositiveNeuralCloud Solutions, a subsidiary of AI/ML Innovations, has obtained ISO 13485:2016 certification under the Medical Device Single Audit Program for its quality management system covering the design, development, production, and distribution of ECG-...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 03, 2026